capital one dsip DSIP (Delta Sleep Inducing Peptide)

Retatrutide is a triple agonist acting on GLP-1, GIP, and glucagon receptors, with phase 2 data published in the New England Journal of Medicine (2023) showing substantial weight reduction

Pentadecapeptide BPC 157 Counteracts L-NAME-Induced Catalepsy

Cagrilintide also shows an ability to reduce overall caloric intake and food cravings , particularly for high-fat or high-sugar foods

Today, we are previewing seven Phase 3 clinical trials focusing on obesity/weight loss that have anticipated completion dates that fall within now and the end of 2027

Together these findings suggest that the elimination of senescent cells through vaccination targeting GPNMB-expressing cells could be beneficial to health span and possibly extend lifespan